As expected, the European Commission approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies’ Spravato (esketamine) nasal spray for the treatment of adults with treatment-resistant major depressive disorder.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
Shares up 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.